the fact that there appears to be a risk in america , where most of the oestrogenic preparations used are based on conjugated equine oestrogens , but not in finland , where the preference is for preparations based on oestriol and oestradiol and where conjugated oestrogen preparations are relatively rarely used , supports the hypothesis that the risk depends on the type of oestrogen used .
C0014938
conjugated oestrogen preparations
C0014939
oestrogen